CN117547478B - Anti-saccharification and anti-aging composition and application thereof in preparation of skin care products - Google Patents
Anti-saccharification and anti-aging composition and application thereof in preparation of skin care products Download PDFInfo
- Publication number
- CN117547478B CN117547478B CN202410045912.4A CN202410045912A CN117547478B CN 117547478 B CN117547478 B CN 117547478B CN 202410045912 A CN202410045912 A CN 202410045912A CN 117547478 B CN117547478 B CN 117547478B
- Authority
- CN
- China
- Prior art keywords
- parts
- glycation
- age
- saccharification
- aging composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims description 5
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 32
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 19
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940074360 caffeic acid Drugs 0.000 claims abstract description 16
- 235000004883 caffeic acid Nutrition 0.000 claims abstract description 16
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims abstract description 16
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 15
- 108010087806 Carnosine Proteins 0.000 claims abstract description 15
- 102000016943 Muramidase Human genes 0.000 claims abstract description 15
- 108010014251 Muramidase Proteins 0.000 claims abstract description 15
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 15
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 15
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 15
- 229940044199 carnosine Drugs 0.000 claims abstract description 15
- 229960000274 lysozyme Drugs 0.000 claims abstract description 15
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 15
- 239000004325 lysozyme Substances 0.000 claims abstract description 15
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 14
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 14
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 14
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 12
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 11
- 239000006002 Pepper Substances 0.000 claims abstract description 11
- 241000722363 Piper Species 0.000 claims abstract description 11
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 11
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 11
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 11
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 11
- 239000011677 pyridoxine Substances 0.000 claims abstract description 11
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- -1 skin conditioner Substances 0.000 claims description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 2
- 229940075559 piperine Drugs 0.000 claims 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 2
- 235000019100 piperine Nutrition 0.000 claims 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 230000004071 biological effect Effects 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 23
- 239000000839 emulsion Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001804 emulsifying effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003906 humectant Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- APZYKUZPJCQGPP-UHFFFAOYSA-N Tetrahydropiperine Chemical compound C=1C=C2OCOC2=CC=1CCCCC(=O)N1CCCCC1 APZYKUZPJCQGPP-UHFFFAOYSA-N 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses an anti-saccharification and anti-aging composition and application thereof in preparing skin care products, wherein the composition comprises the following components in parts by weight: 0.01-3 parts of nicotinamide, 0.1-5 parts of carnosine, 0.01-5 parts of lipoic acid, 0.01-1 part of lysozyme, 0.01-0.25 part of caffeic acid, 0.001-0.05 part of pepper seed extract, 0.01-2 parts of pyridoxine and 0.001-0.5 part of pH regulator. The nicotinamide, carnosine, lipoic acid and pipolyamine can inhibit the formation of AGE, the lysozyme can effectively remove the AGE, and the caffeic acid can block the biological effect of the AGE, namely inhibit adverse reaction of the AGE on skin, and the antioxidant and anti-aging effects of the pepper seed extract and the transdermal absorption effect of the anti-saccharification functional components are obviously improved, so that the components have a synergistic effect, and the anti-saccharification and anti-aging effects are obviously improved.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to an anti-saccharification and anti-aging composition and application thereof in preparing skin care products.
Background
The Non-enzymatic glycosylation (Non-enzymatic glycation, NEG) reaction is commonly known as saccharification, a concept which was first proposed by french Louis Camille Maillard in 1912 to describe a reaction of glycine with glucose to form brown melanoidin, and is therefore also known as Maillard (Maillard) reaction. Refers to the process of final production of advanced glycosylation end products (advanced glycationend product, AGE) by a series of reactions such as condensation, rearrangement, cleavage, oxidative modification and the like of free amino groups on macromolecules such as proteins, amino acids, lipids or nucleic acids and carbonyl groups on reducing sugars (such as glucose) under non-enzymatic conditions. AGE is closely related to skin aging, excessive AGE can undergo saccharification and crosslinking reaction with skin elastic fiber and collagen, and AGE is brown, and finally skin is yellowing and elasticity is reduced. Thereby accelerating skin aging.
With the improvement of the living standard of people, the cosmetic skin care product plays an increasingly important role in the daily life of people. In recent years, research strength is increased in anti-saccharification of skin care products at home and abroad. There are a number of drawbacks and disadvantages. At present, the anti-saccharification skin care product has unilateral performance, and single raw materials with AGE formation inhibition function or superposition of several raw materials with the same attribute are used in many cases. Not considered from the anti-glycation logic and path. No comprehensive consideration is given to the skin effect from the saccharification reaction and its formation of AGE as a product, factors influencing AGE formation, AGE. The composition developed by the invention solves the problems of saccharification resistance and aging resistance in three dimensions: the first effective inhibition of AGE formation; a second accelerated AGE decomposition; and thirdly, blocking the AGE biological effect, namely, adverse reaction brought to the skin. Moreover, the anti-saccharification and anti-aging composition strengthens transdermal absorption, and the anti-saccharification and anti-aging effects are obviously improved.
Disclosure of Invention
Therefore, the invention aims to provide an anti-saccharification and anti-aging composition and application thereof in preparing skin care products, and the composition has high AGE inhibition rate under the synergistic effect of various components through reasonable proportion of various components, and has good anti-saccharification and anti-aging effects.
Specifically, the invention is realized through the following technical schemes:
in a first aspect, the present invention provides an anti-glycation, anti-aging composition comprising the following components in parts by weight: 0.01-3 parts of nicotinamide, 0.1-5 parts of carnosine, 0.01-5 parts of lipoic acid, 0.01-1 part of lysozyme, 0.01-0.25 part of caffeic acid, 0.001-0.05 part of pepper seed extract, 0.01-2 parts of pyridoxine and 0.001-0.5 part of pH regulator.
Preferably, the anti-saccharification and anti-aging composition comprises the following components in parts by weight: 0.1-3 parts of nicotinamide, 0.1-3 parts of carnosine, 0.1-5 parts of lipoic acid, 0.1-1 part of lysozyme, 0.1-0.25 part of caffeic acid, 0.01-0.05 part of pepper seed extract, 0.1-2 parts of pyridoxine and 0.005-0.3 part of pH regulator.
More preferably, the anti-saccharification and anti-aging composition comprises the following components in parts by weight: 0.2-2 parts of nicotinamide, 0.1-1 part of carnosine, 0.1-2 parts of lipoic acid, 0.2-1 part of lysozyme, 0.1-0.25 part of caffeic acid, 0.01-0.05 part of pepper seed extract, 0.1-2 parts of pyridoxine and 0.005-0.1 part of pH regulator.
In one embodiment, the anti-glycation, anti-aging composition further comprises a balance of a skin care product matrix.
The skin care product matrix is a basic substance for forming the skin care product, and can be selected by a person skilled in the art according to the design requirements of the product and the dosage form of the product.
Preferably, the skin care product matrix comprises at least one of grease, an emulsifying agent, a humectant, a solvent, a skin conditioning agent, a thickening agent, perfume and a bacteriostatic agent.
The grease, emulsifier, humectant, solvent, skin conditioner, thickener, perfume, and bacteriostat may be selected according to conventional procedures in the art.
In one embodiment, in the above anti-glycation, anti-aging composition, the nicotinamide is greater than 99% pure and the niacin content is less than 100 ppm; the carnosine purity is greater than 95%; the lipoic acid purity is greater than 99%; the caffeic acid purity is greater than 99%; the purity of the pyridoxine is more than 98%.
In one embodiment, in the anti-saccharification and anti-aging composition, the enzyme activity of the lysozyme is more than 18000U/mg, and the solubility is not less than 95%.
In one embodiment, the content of tetrahydropiperine in the piper nigrum seed extract in the anti-glycation, anti-aging composition is greater than 98%.
In one embodiment, in the above anti-saccharification and anti-aging composition, the pH adjustor is citric acid and is used for adjusting the system ph=4.5-5.5.
In a second aspect, the invention provides the use of an anti-glycation, anti-aging composition as described above in the preparation of a skin care product.
The skin care products include, but are not limited to, lotions, essences, creams, lotions, gels, masks, and the like.
The skin care products provided herein may be prepared by any suitable method known in the art. For example, the skin care product is prepared by using equipment such as emulsifying pot, dissolving equipment, disperser, and conveying pump which are commonly used in the field of skin care products.
The components of the invention have the following functions:
nicotinamide can remarkably inhibit AGE formation, and has anti-glycation and anti-free radical effects. Can be left on the surface of skin or can be deep into the skin. The invention selects high-purity nicotinamide, has extremely low nicotinic acid content and does not generate irritation to skin.
Carnosine is a dipeptide consisting of two amino acids, β -alanine and L-histidine. Carnosine can achieve the effect of resisting cell aging by protecting mitochondrial function and reducing the generation of active oxygen free radicals; it also can protect protein from glycosylation, and has anti-glycation effect. The invention selects high-purity carnosine, which is safe and effective.
Lipoic acid is used as a therapeutic drug for diabetes at the beginning, and has a main effect of preventing sugar from binding with protein, that is, has an anti-glycation effect, and thus can easily stabilize the blood sugar level, so that it is used as a vitamin for improving metabolism, and is administered to liver disease patients and diabetics. The high-purity lipoic acid is selected, has good skin permeability, can better remove free radicals in skin, inhibit formation of AGE, and realize anti-glycation and anti-aging effects of skin.
Animal experiments prove that the lysozyme can promote the clearance of AGE in vivo and can obviously delay and reduce the occurrence and development of diabetic nephropathy in rats. The chromatographic column covalently coupled with lysozyme can effectively remove AGE in blood serum of diabetics by more than 60 percent in vitro test. The lysozyme is selected to effectively remove the AGE of the skin, so that the development of glycosylation reaction can be delayed.
Caffeic acid can inhibit AGE and NF- κB signaling, reduce endoplasmic reticulum stress and inflammatory factor release, reduce cell damage and relieve glomerular fibrosis. Caffeic acid has effects of scavenging free radicals, resisting oxidation mechanism, promoting autophagy, relieving inflammatory reaction, inhibiting related enzyme activity, etc., and can be used for well relieving diabetic nephropathy development. The caffeic acid is mainly used for blocking biological effects of the AGE, namely inhibiting adverse reactions of the AGE on the skin.
The pepper seed extract has the effects of resisting oxidation and aging, has the effect of promoting permeation, and can remarkably improve the transdermal absorption of the anti-saccharification functional components.
The pyridoxine can compete with glucose for the lysine amino group of Hb molecule, making glycosylation reaction weak. The inhibition of HbA1C formation by piuramine was enhanced with increasing concentration, demonstrating the intervention of piuramine on the non-enzymatic glycosylation early reaction. The content of collagen AGE in skin can be reduced by the piuramine, and the piuramine is also an effective free radical scavenger, so that lipid peroxidation and glycosylation reactions can be reduced. And the pyrilamine is a vitamin B6 derivative, has almost no toxic or harmful effect on human bodies, and is safe to use.
The pH of the system can be adjusted to 4.5-5.5 by the citric acid, which is favorable for the components such as the pyradipamine, the caffeic acid and the like to fully play roles.
Compared with the prior art, the invention has the following beneficial effects:
(1) In the anti-saccharification and anti-aging composition provided by the invention, nicotinamide, carnosine, lipoic acid and pyridoxine can inhibit the formation of AGE, lysozyme can accelerate the decomposition of AGE and effectively remove the AGE, and caffeic acid can block the biological effect of AGE, namely inhibit adverse reaction of AGE on skin, and then the anti-oxidization and anti-aging effects of the pepper seed extract are combined and the transdermal absorption effect of the anti-saccharification effect component is obviously improved, so that the components in the composition have a synergistic effect, and the anti-saccharification and anti-aging effects are obviously improved.
(2) The anti-saccharification and anti-aging composition provided by the invention adopts specific components in specific proportions, and has the advantages of reasonable formula, convenience in use, good skin absorption effect, no irritation and high safety.
Detailed Description
The following detailed description of the embodiments of the present invention is provided for better illustration of the present invention, but is not to be construed as limiting the invention.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.
The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, are all commercially available products.
Examples 1 to 4
An emulsion prepared from the anti-saccharification and anti-aging composition. Emulsions of examples 1-4 and blank were prepared according to the components and contents (unit: wt%) shown in table 1 below:
TABLE 1
Comparative examples 1 to 8
Emulsions of comparative examples 1 to 8 were prepared according to the components and contents (unit: wt%) shown in the following table 2:
TABLE 2
The preparation method of the emulsions of examples 1-4, comparative examples 1-8 and blank examples comprises the following steps according to the amounts shown in tables 1 and 2:
(1) Adding olive oil and emulsifier lecithin into an oil phase pot, stirring and heating to 75 ℃, and completely melting;
(2) Adding part of water, part of humectant hyaluronic acid, thickener sodium alginate, pH regulator citric acid and 1, 2-pentanediol into an emulsifying pot, stirring and heating to 75 ℃, and dissolving completely;
(3) Pumping the materials in the oil phase pot into the emulsifying pot, homogenizing and emulsifying for 6-8 minutes, preserving heat for 10 minutes, and then cooling;
(4) When the temperature is reduced to 40 ℃, dissolving nicotinamide, carnosine, lipoic acid, lysozyme, caffeic acid and pyruvic polyamine with the sterilized residual water, dissolving the pepper seed extract with the residual humectant hyaluronic acid, adding the solution and geraniol into an emulsifying pot, and stirring for 30 minutes;
(5) And (5) discharging after sampling and checking to be qualified.
Example 5
Anti-glycation efficacy evaluation test of the emulsion prepared by using the anti-glycation and anti-aging composition
Conventional AGE has fluorescent characteristic, and the experimental example uses the principle that glucose and bovine serum albumin undergo saccharification reaction in vitro to form AGE to carry out modeling treatment, and the anti-saccharification effect is evaluated by calculating the AGE inhibition rate through a fluorescence quantification method after adding emulsion prepared by the anti-saccharification and anti-aging composition.
1. Test materials and instruments
1.1 test reagents
Bovine serum albumin (bovine serum albumin, BSA), glucose: analytically pure, sigma, usa.
1.2 test samples
Emulsions prepared with anti-glycation, anti-aging compositions of examples 1-4, comparative examples 1-8 and blank examples.
1.3 test instruments
Microplate reader (Synergy H1), bio-Tek company, america.
2. Test method
2.1 establishment of in vitro protein AGE Forming System
Phosphate buffer solution with pH value of 7.4 is used as matrix solution to prepare liquid with final concentration of bovine serum albumin with volume fraction of 5% and glucose with concentration of 1 mol/L, all the above liquid are sterilized and filtered by 0.2 μm filter membrane, and the above liquid is packaged in 1.5 mL tip centrifuge tube. The incubation was continued for 3d at 60℃with oxygen and light protection. The OD of the AGE formed was determined by a microplate reader (Synergy H1, bio-Tek) (detection wavelength 370 nm, reference wavelength 440 nm).
2.2 in vitro determination of inhibition of AGE formation
Mixed incubations containing the emulsions prepared in examples 1-4 and comparative examples 1-8 were prepared with a liquid containing 5% bovine serum albumin and 1 mol/L glucose, respectively. The control group (blank) is a protein high sugar liquid containing no test substance. All the above liquids were sterilized and filtered with 0.2 μm filter membrane and packed in 1.5. 1.5 mL pointed centrifuge tubes. The incubation was continued for 3d at 60℃with oxygen and light protection. The OD of the AGE formed was determined by a microplate reader (Synergy H1, bio-Tek) (detection wavelength 370 nm, reference wavelength 440 nm).
2.3 data processing and statistical analysis methods (at least 3 replicates per set of experiments)
Calculating the AGE inhibition rate by using a formula;
AGE inhibition = (C-T)/c×100
Wherein, C is the fluorescence intensity of the control group (blank), i.e., the intensity of the glycosylated bovine serum albumin in the absence of the anti-glycation, anti-aging composition;
t is the strength of the glycosylated bovine serum albumin in the presence of the anti-glycosylated, anti-aging composition.
3. Test results
The inhibition effect of the test samples on AGE is shown in table 3.
Table 3: AGE inhibition of emulsions prepared with anti-glycation and anti-aging compositions of examples 1-4, comparative examples 1-8 and blank examples
As can be seen from Table 3, the emulsions of examples 1-4 prepared with the anti-glycation, anti-aging compositions of the present invention had high AGE inhibition, whereas the emulsions of comparative examples 1-8 prepared with the anti-glycation, anti-aging compositions lacking any one of the efficacy components had significantly reduced AGE inhibition. Therefore, the components in the composition have a synergistic effect, and the AGE inhibition effect is obviously improved, namely the anti-saccharification effect is obviously improved.
Example 6
Anti-aging efficacy test of the emulsion prepared by using anti-saccharification and anti-aging composition
The evaluation method is as follows: by using a VISIA tester, 104 subjects are selected to be 13 groups, 8 persons in each group are aged 35-55 years, and the subjects have the phenomena of dark yellow skin, wrinkles, reduced elasticity of collagen fibers, dark brown spots and the like. And the subject is healthy, has no history of skin diseases and allergies, is not sensitive to skin, and can use skin care products according to specifications. Each group of subjects sprayed the face with the emulsions prepared in examples 1 to 4, comparative examples 1 to 8, and blank examples, respectively, once a day, each morning and evening, for 3 months continuously, and compared with the skin condition before and after 3 months, and the wrinkle reduction rate, skin color lightening rate, and skin elasticity lightening rate of each group of subjects were calculated. The test results are shown in Table 4.
Table 4: anti-aging Effect of emulsions prepared with anti-saccharification and anti-aging compositions of examples 1-4, comparative examples 1-8 and blank examples
As can be seen from Table 4, the emulsions of examples 1 to 4 prepared using the anti-glycation and anti-aging composition of the present invention significantly reduced skin wrinkles, brightened skin tone and improved skin elasticity, as compared to the emulsions of comparative examples 1 to 8 prepared using the anti-glycation and anti-aging composition lacking any one of the effective components. Therefore, the components in the composition have a synergistic effect, and the anti-aging effect is remarkably improved.
It is apparent that the above examples are only illustrative of the present invention and are not limiting of the embodiments of the present invention. Various modifications and alterations of this invention may be made by those skilled in the art without departing from the spirit and scope of this invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (10)
1. An anti-saccharification and anti-aging composition is characterized by comprising the following components in parts by weight: 0.01-3 parts of nicotinamide, 0.1-5 parts of carnosine, 0.01-5 parts of lipoic acid, 0.01-1 part of lysozyme, 0.01-0.25 part of caffeic acid, 0.001-0.05 part of pepper seed extract, 0.01-2 parts of pyridoxine and 0.001-0.5 part of pH regulator.
2. The anti-glycation, anti-aging composition of claim 1, wherein the composition comprises the following components in parts by weight: 0.1-3 parts of nicotinamide, 0.1-3 parts of carnosine, 0.1-5 parts of lipoic acid, 0.1-1 part of lysozyme, 0.1-0.25 part of caffeic acid, 0.01-0.05 part of pepper seed extract, 0.1-2 parts of pyridoxine and 0.005-0.3 part of pH regulator.
3. The anti-glycation, anti-aging composition of claim 1, wherein the composition comprises the following components in parts by weight: 0.2-2 parts of nicotinamide, 0.1-1 part of carnosine, 0.1-2 parts of lipoic acid, 0.2-1 part of lysozyme, 0.1-0.25 part of caffeic acid, 0.01-0.05 part of pepper seed extract, 0.1-2 parts of pyridoxine and 0.005-0.1 part of pH regulator.
4. The anti-glycation, anti-aging composition of claim 1, wherein the composition further comprises a balance of a skin care product base.
5. The anti-glycation, anti-aging composition of claim 4, wherein the skin care product base comprises at least one of grease, emulsifier, moisturizer, solvent, skin conditioner, thickener, perfume, bacteriostat.
6. The anti-glycation, anti-aging composition of claim 1, wherein the nicotinamide is greater than 99% pure and niacin content is less than 100 ppm; the carnosine purity is greater than 95%; the lipoic acid purity is greater than 99%; the caffeic acid purity is greater than 99%; the purity of the pyridoxine is more than 98%.
7. The anti-glycation, anti-aging composition of claim 1, wherein the lysozyme has an enzyme activity greater than 18000U/mg and a solubility of not less than 95%.
8. The anti-glycation, anti-aging composition of claim 1, wherein the piperine content of the piperine extract is greater than 98%.
9. The anti-glycation, anti-aging composition of claim 1, wherein the pH adjuster is citric acid for adjusting the system pH = 4.5-5.5.
10. Use of an anti-glycation and anti-aging composition according to any one of claims 1-9 for the preparation of a skin care product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410045912.4A CN117547478B (en) | 2024-01-12 | 2024-01-12 | Anti-saccharification and anti-aging composition and application thereof in preparation of skin care products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410045912.4A CN117547478B (en) | 2024-01-12 | 2024-01-12 | Anti-saccharification and anti-aging composition and application thereof in preparation of skin care products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117547478A CN117547478A (en) | 2024-02-13 |
| CN117547478B true CN117547478B (en) | 2024-03-26 |
Family
ID=89821938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410045912.4A Active CN117547478B (en) | 2024-01-12 | 2024-01-12 | Anti-saccharification and anti-aging composition and application thereof in preparation of skin care products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117547478B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007254387A (en) * | 2006-03-23 | 2007-10-04 | Showa Denko Kk | Antiaging cosmetic |
| CN109172491A (en) * | 2018-11-22 | 2019-01-11 | 赛杜恳医药生物科技（上海）有限公司 | A kind of creme and preparation method thereof with anti-aging and activating microcirculation and removing stasis medicinal function |
| CN112472638A (en) * | 2019-10-10 | 2021-03-12 | 广东丸美生物技术股份有限公司 | Anti-aging matrix and preparation method and application thereof |
| CN112618468A (en) * | 2020-10-27 | 2021-04-09 | 苏州讯如电子科技有限公司 | Efficient anti-sugar essence and preparation method thereof |
| CN113230177A (en) * | 2021-06-08 | 2021-08-10 | 吴东文 | Anti-aging skin care essence and preparation method thereof |
| CN116172901A (en) * | 2023-01-10 | 2023-05-30 | 义乌市欧雅化妆品有限公司 | Anti-aging composition and preparation method and application thereof |
-
2024
- 2024-01-12 CN CN202410045912.4A patent/CN117547478B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007254387A (en) * | 2006-03-23 | 2007-10-04 | Showa Denko Kk | Antiaging cosmetic |
| CN109172491A (en) * | 2018-11-22 | 2019-01-11 | 赛杜恳医药生物科技（上海）有限公司 | A kind of creme and preparation method thereof with anti-aging and activating microcirculation and removing stasis medicinal function |
| CN112472638A (en) * | 2019-10-10 | 2021-03-12 | 广东丸美生物技术股份有限公司 | Anti-aging matrix and preparation method and application thereof |
| CN112618468A (en) * | 2020-10-27 | 2021-04-09 | 苏州讯如电子科技有限公司 | Efficient anti-sugar essence and preparation method thereof |
| CN113230177A (en) * | 2021-06-08 | 2021-08-10 | 吴东文 | Anti-aging skin care essence and preparation method thereof |
| CN116172901A (en) * | 2023-01-10 | 2023-05-30 | 义乌市欧雅化妆品有限公司 | Anti-aging composition and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117547478A (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0343694A2 (en) | Agent for the treatmment and protection of the skin | |
| WO2017038951A1 (en) | External preparation for skin for reducing skin yellowness | |
| CN114344352A (en) | Composition with effect of resisting advanced glycosylation end products and application thereof | |
| CN117547478B (en) | Anti-saccharification and anti-aging composition and application thereof in preparation of skin care products | |
| EP0949919A1 (en) | A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions | |
| CN111956535A (en) | Conditioner composition and preparation method and application thereof | |
| EP3661534B1 (en) | A synergistic composition as a promoter of autophagy | |
| JP3977889B2 (en) | Drugs containing buckwheat husk extract as an active ingredient | |
| US20120231071A1 (en) | Natural product inhibitors of 3dg | |
| CN115531244A (en) | Composition and preparation method and application thereof | |
| CN111135124A (en) | Skin external composition containing mixture of sucrose, indole-3-acetic acid and rose hip extract | |
| CN114099366B (en) | Sterile anti-aging wrinkle-removing combined liquid for promoting cell energy metabolism and preparation method and application thereof | |
| JP6283054B2 (en) | In vivo Maillard reaction inhibitor or AGEs production inhibitor | |
| JP2000256196A (en) | Anti-inflammatory and anti-allergic medicine | |
| JP2012193174A (en) | Maillard reaction inhibitor composition in living body containing tranexamic acid | |
| KR102337297B1 (en) | Cosmetic or pharmaceutical composition for skin elasticity, anti-wrinkle, or skin moisturizing comprising sophoricoside or a pharmaceutically acceptable salt thereof | |
| CN116235948B (en) | Anti-saccharification composition and application thereof | |
| JP6027752B2 (en) | AGEs production inhibitor | |
| JPH06192082A (en) | Improver for senescence of cell membrane | |
| KR20160019769A (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising cordycepin or a pharmaceutically acceptable salt thereof | |
| CN117257664A (en) | Anti-saccharification and anti-oxidation composition, anti-aging face cream and preparation method of anti-saccharification and anti-oxidation composition | |
| WO2023194567A1 (en) | Oral composition containing dimethylglycine for improving the condition of the hair and scalp | |
| CN116570544A (en) | Anti-saccharification emulsion and preparation method and application thereof | |
| Soban et al. | The Effect of Glutathione as an Adjuvant Therapy for Skin Whitening and Hyperpigmentation in Type 2 Diabetes | |
| CN113876706A (en) | Anthocyanin suspension eye drops and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |